AAPL345.28-3.63 (-1.04%) ▼|ABBV296.50+5.71 (+1.96%) ▲|ABT106.24+1.67 (+1.60%) ▲|ACN252.82+5.60 (+2.27%) ▲|ADBE254.32+6.20 (+2.50%) ▲|AMAT398.75-22.92 (-5.43%) ▼|AMD512.09-54.33 (-9.59%) ▼|AMGN470.64+9.91 (+2.15%) ▲|AMT187.51+1.63 (+0.88%) ▲|AMZN236.35-7.44 (-3.05%) ▼|AVGO328.06-16.94 (-4.91%) ▼|AXP319.58-4.13 (-1.28%) ▼|BA172.97+0.32 (+0.19%) ▲|BAC50.21-0.94 (-1.83%) ▼|BKNG148.89-1.55 (-1.03%) ▼|BLK1,154.76-21.49 (-1.83%) ▼|BMY62.86+1.47 (+2.39%) ▲|BNY147.39-1.98 (-1.33%) ▼|BRK-B545.63+3.67 (+0.68%) ▲|C121.93-3.83 (-3.05%) ▼|CAT634.18-13.21 (-2.04%) ▼|CL95.49+2.33 (+2.50%) ▲|CMCSA22.96+0.69 (+3.08%) ▲|COF204.92-3.82 (-1.83%) ▼|COP152.18+2.15 (+1.43%) ▲|COST1,011.58+16.97 (+1.71%) ▲|CRM230.96+0.06 (+0.02%) ▲|CSCO104.10-4.50 (-4.14%) ▼|CVS90.60+0.27 (+0.30%) ▲|CVX235.88+4.42 (+1.91%) ▲|DE671.37+11.37 (+1.72%) ▲|DHR233.94-3.04 (-1.28%) ▼|DIS111.54+0.63 (+0.56%) ▲|DUK127.48+1.58 (+1.26%) ▲|EMR167.35-3.39 (-1.99%) ▼|FDX316.55+8.73 (+2.84%) ▲|GD376.54+5.72 (+1.54%) ▲|GE305.51-7.55 (-2.41%) ▼|GEV865.54-22.31 (-2.51%) ▼|GILD171.89+6.28 (+3.79%) ▲|GM85.91+0.19 (+0.22%) ▲|GOOG278.53-3.79 (-1.34%) ▼|GOOGL279.67-4.15 (-1.46%) ▼|GS895.67-32.07 (-3.46%) ▼|HD328.79-0.19 (-0.06%) ▼|HON219.91-2.23 (-1.00%) ▼|IBM256.38-1.90 (-0.74%) ▼|INTC66.03-26.05 (-28.29%) ▼|INTU340.69+9.50 (+2.87%) ▲|ISRG444.16-4.60 (-1.03%) ▼|JNJ277.09+1.89 (+0.69%) ▲|JPM337.20-6.38 (-1.86%) ▼|KO94.47+1.65 (+1.78%) ▲|LIN513.79+10.64 (+2.11%) ▲|LLY1,427.41+53.71 (+3.91%) ▲|LMT642.47-1.12 (-0.17%) ▼|LOW208.43+1.15 (+0.55%) ▲|LRCX242.06-12.33 (-4.85%) ▼|MA633.48-2.22 (-0.35%) ▼|MCD258.83+1.45 (+0.56%) ▲|MDLZ64.59+2.06 (+3.29%) ▲|MDT97.24+0.13 (+0.13%) ▲|META618.49-6.03 (-0.97%) ▼|MMM176.45-0.91 (-0.51%) ▼|MO77.95+1.20 (+1.56%) ▲|MRK148.90+2.57 (+1.76%) ▲|MS184.46-4.40 (-2.33%) ▼|MSFT521.48-8.67 (-1.63%) ▼|MU892.51-41.76 (-4.47%) ▼|NEE83.43+1.29 (+1.57%) ▲|NFLX62.53+0.48 (+0.77%) ▲|NKE38.89+0.47 (+1.21%) ▲|NOW107.09-2.59 (-2.36%) ▼|NVDA206.79-6.87 (-3.22%) ▼|ORCL133.51-6.05 (-4.34%) ▼|PEP136.21+2.42 (+1.81%) ▲|PFE30.32+0.37 (+1.22%) ▲|PG163.24+2.65 (+1.65%) ▲|PLTR187.24-9.18 (-4.67%) ▼|PM210.36+1.86 (+0.89%) ▲|QCOM167.72-17.69 (-9.54%) ▼|RTX200.05+0.65 (+0.33%) ▲|SBUX103.34-2.17 (-2.06%) ▼|SCHW88.66-0.82 (-0.91%) ▼|SO94.04+1.05 (+1.12%) ▲|SPG216.89+1.17 (+0.54%) ▲|T21.46+0.54 (+2.56%) ▲|TMO703.64-5.54 (-0.78%) ▼|TMUS155.31+8.02 (+5.45%) ▲|TSLA396.93-6.37 (-1.58%) ▼|TXN302.07-9.35 (-3.00%) ▼|UBER65.09-0.65 (-0.99%) ▼|UNH408.45-2.46 (-0.60%) ▼|UNP302.17+0.24 (+0.08%) ▲|UPS108.29+0.96 (+0.90%) ▲|USB59.98-0.66 (-1.09%) ▼|V413.10+2.56 (+0.62%) ▲|VZ44.83+1.17 (+2.67%) ▲|WFC83.93-0.89 (-1.04%) ▼|WMT123.13+1.88 (+1.55%) ▲|XOM187.59+4.30 (+2.35%) ▲|AAPL345.28-3.63 (-1.04%) ▼|ABBV296.50+5.71 (+1.96%) ▲|ABT106.24+1.67 (+1.60%) ▲|ACN252.82+5.60 (+2.27%) ▲|ADBE254.32+6.20 (+2.50%) ▲|AMAT398.75-22.92 (-5.43%) ▼|AMD512.09-54.33 (-9.59%) ▼|AMGN470.64+9.91 (+2.15%) ▲|AMT187.51+1.63 (+0.88%) ▲|AMZN236.35-7.44 (-3.05%) ▼|AVGO328.06-16.94 (-4.91%) ▼|AXP319.58-4.13 (-1.28%) ▼|BA172.97+0.32 (+0.19%) ▲|BAC50.21-0.94 (-1.83%) ▼|BKNG148.89-1.55 (-1.03%) ▼|BLK1,154.76-21.49 (-1.83%) ▼|BMY62.86+1.47 (+2.39%) ▲|BNY147.39-1.98 (-1.33%) ▼|BRK-B545.63+3.67 (+0.68%) ▲|C121.93-3.83 (-3.05%) ▼|CAT634.18-13.21 (-2.04%) ▼|CL95.49+2.33 (+2.50%) ▲|CMCSA22.96+0.69 (+3.08%) ▲|COF204.92-3.82 (-1.83%) ▼|COP152.18+2.15 (+1.43%) ▲|COST1,011.58+16.97 (+1.71%) ▲|CRM230.96+0.06 (+0.02%) ▲|CSCO104.10-4.50 (-4.14%) ▼|CVS90.60+0.27 (+0.30%) ▲|CVX235.88+4.42 (+1.91%) ▲|DE671.37+11.37 (+1.72%) ▲|DHR233.94-3.04 (-1.28%) ▼|DIS111.54+0.63 (+0.56%) ▲|DUK127.48+1.58 (+1.26%) ▲|EMR167.35-3.39 (-1.99%) ▼|FDX316.55+8.73 (+2.84%) ▲|GD376.54+5.72 (+1.54%) ▲|GE305.51-7.55 (-2.41%) ▼|GEV865.54-22.31 (-2.51%) ▼|GILD171.89+6.28 (+3.79%) ▲|GM85.91+0.19 (+0.22%) ▲|GOOG278.53-3.79 (-1.34%) ▼|GOOGL279.67-4.15 (-1.46%) ▼|GS895.67-32.07 (-3.46%) ▼|HD328.79-0.19 (-0.06%) ▼|HON219.91-2.23 (-1.00%) ▼|IBM256.38-1.90 (-0.74%) ▼|INTC66.03-26.05 (-28.29%) ▼|INTU340.69+9.50 (+2.87%) ▲|ISRG444.16-4.60 (-1.03%) ▼|JNJ277.09+1.89 (+0.69%) ▲|JPM337.20-6.38 (-1.86%) ▼|KO94.47+1.65 (+1.78%) ▲|LIN513.79+10.64 (+2.11%) ▲|LLY1,427.41+53.71 (+3.91%) ▲|LMT642.47-1.12 (-0.17%) ▼|LOW208.43+1.15 (+0.55%) ▲|LRCX242.06-12.33 (-4.85%) ▼|MA633.48-2.22 (-0.35%) ▼|MCD258.83+1.45 (+0.56%) ▲|MDLZ64.59+2.06 (+3.29%) ▲|MDT97.24+0.13 (+0.13%) ▲|META618.49-6.03 (-0.97%) ▼|MMM176.45-0.91 (-0.51%) ▼|MO77.95+1.20 (+1.56%) ▲|MRK148.90+2.57 (+1.76%) ▲|MS184.46-4.40 (-2.33%) ▼|MSFT521.48-8.67 (-1.63%) ▼|MU892.51-41.76 (-4.47%) ▼|NEE83.43+1.29 (+1.57%) ▲|NFLX62.53+0.48 (+0.77%) ▲|NKE38.89+0.47 (+1.21%) ▲|NOW107.09-2.59 (-2.36%) ▼|NVDA206.79-6.87 (-3.22%) ▼|ORCL133.51-6.05 (-4.34%) ▼|PEP136.21+2.42 (+1.81%) ▲|PFE30.32+0.37 (+1.22%) ▲|PG163.24+2.65 (+1.65%) ▲|PLTR187.24-9.18 (-4.67%) ▼|PM210.36+1.86 (+0.89%) ▲|QCOM167.72-17.69 (-9.54%) ▼|RTX200.05+0.65 (+0.33%) ▲|SBUX103.34-2.17 (-2.06%) ▼|SCHW88.66-0.82 (-0.91%) ▼|SO94.04+1.05 (+1.12%) ▲|SPG216.89+1.17 (+0.54%) ▲|T21.46+0.54 (+2.56%) ▲|TMO703.64-5.54 (-0.78%) ▼|TMUS155.31+8.02 (+5.45%) ▲|TSLA396.93-6.37 (-1.58%) ▼|TXN302.07-9.35 (-3.00%) ▼|UBER65.09-0.65 (-0.99%) ▼|UNH408.45-2.46 (-0.60%) ▼|UNP302.17+0.24 (+0.08%) ▲|UPS108.29+0.96 (+0.90%) ▲|USB59.98-0.66 (-1.09%) ▼|V413.10+2.56 (+0.62%) ▲|VZ44.83+1.17 (+2.67%) ▲|WFC83.93-0.89 (-1.04%) ▼|WMT123.13+1.88 (+1.55%) ▲|XOM187.59+4.30 (+2.35%) ▲|
15.1 C
New York
Friday, October 30, 2026

Tag: result

newsFORsourcecompanycontentinformationreleases1market

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of...

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

AES Stockholders Approve Acquisition by Global Infrastructure Partners and EQT-Led Consortium

ARLINGTON, Va., June 26, 2026 /PRNewswire/ -- The AES Corporation (the "Company" or "AES") (NYSE: AES) today announced that its stockholders voted to approve...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Hearing Notice – CIRO to Hold a Settlement Hearing for George Alexander Abisaleh

TORONTO, June 26, 2026 /CNW/ - A hearing has been scheduled before a hearing panel of the Canadian Investment Regulatory Organization (CIRO) pursuant to...

Building Stronger Systems for Newborn Screening, Diagnosis and Management of Congenital Conditions: New WHO report highlights scalable solutions to save lives and prevent disability

CHAPEL HILL, N.C., June 26, 2026 /PRNewswire/ -- Ahead of International Neonatal Screening Day on June 28, MiracleFeet, a global nonprofit providing access to clubfoot...

Civitas Closes $44 Million Senior Loan for Phase I of a Master-Planned Community in Colorado’s Aspen Region

DALLAS, June 26, 2026 /PRNewswire/ -- Civitas Capital Group announced the closing of a $44 million senior loan to finance "phase one" land and infrastructure development of Harvest Village,...

URBAN OUTFITTERS AND DOORDASH CELEBRATE THE CLASS OF 2030 WITH THE ULTIMATE GRADUATION CELEBRATION

The brands expand their partnership with a one-of-a-kind experience honoring a remarkable graduate and thousands of surprise deliveries for students nationwidePHILADELPHIA, June 26, 2026...

Kyivstar and VEON Partner with Ministry of Economy, Environment and Agriculture of Ukraine to Accelerate AI Infrastructure and Digital Economy Growth

This strategic initiative with the Ministry of Economy of Ukraine aims to fast-track digital infrastructure development, unlock scalable AI adoption, and underpin sustainable long-term economic growth.

Blue Lizard® Brand Sunscreen Named First Official Sunscreen Partner of the Manning Passing Academy

A Partnership to Showcase the Importance of Sun Safety On and Off the FieldNASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Revance is proud to...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResult

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers